ATLANTIC CITY, N.J. -- Elaine Doherty was the typical patient to whom drug maker Merck &; Co. marketed its former blockbuster painkiller Vioxx: a senior citizen with arthritis and other ailments ...

RIO GRANDE CITY — A $7.75 million jury award over the Merck & Co. drug Vioxx will stand after a judge let the company's request for a new trial expire. Merck made the request after learning that ...

WASHINGTON -- What Merck &; Co. calls good salesmanship -- emphasizing the positive in selling the painkiller Vioxx -- a Democratic congressman says is disinformation designed to deflect safety ...

Merck & Co. withdrew the popular drug Vioxx from the market in September, after data from a clinical trial supported claims the medication was associated with an increased risk of heart attack and ...

The prestigious New England Journal of Medicine is publishing more criticism of a 2000 study on Vioxx. The journal says at least two researchers knew about "adverse cardiovascular events" more than ...

The backlash after the withdrawal of the arthritis drug Vioxx is in full swing. Critics of the pharmaceutical industry and the Food and Drug Administration’s (FDA) effort to modernize the drug ...

The plaintiff in the first federal lawsuit against Merck, makers of the painkiller Vioxx, took the stand Monday in Houston. Evelyn Irvin Plunkett told jurors that her 53-year-old husband, Richard ...

On Friday, the stock price for the pharmaceutical giant Merck dropped 7.7 percent after a Texas jury handed down a $253 million award against the company. The penalty came after the jury found that ...

Join Ringler Radio co-hosts, Larry Cohen and Dennis English from the 2005 ATLA Convention in Toronto for discussion of the compelling issues facing trial lawyers in America today! Our special guests ...

ANGLETON - Lawyers presented two different views of pharmaceutical giant Merck & Co., Inc., in opening arguments today in the country's first trial involving the once popular painkiller Vioxx. David ...

A settlement calling for Merck & Co. to pay $830 million to investors in multidistrict litigation over the painkiller Vioxx and another $232 million in legal fees received preliminary approval Feb. 11 ...

Prague, Czech Republic - A new meta-analysis of the cardiovascular safety profile of the COX-2 inhibitor rofecoxib (Vioxx® - Merck & Co) has shown that the risk of sustaining a thrombotic ...